Gap among BMS, Gilead and Abbvie over hepatitis C treatments
Oral hepatitis C treatments needing no interferon are getting close to commercialization.
In the domestic market, the closest company to commercialization is BMS. The company has acquired an approval for the NS5A replication complex inhibitor ‘Daklinza(daclatasvir)’ in combination with the NS3/4...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
